The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Astragalus membranaceus (AM) is used to treat stroke for a long time, and a number of studies
have shown that AM can reduce cerebral infarction area and has anti-oxidation activity. PG2,
a sterile powder of polysaccharides isolated from the root of astragulus (Huang-Chi) for
intravenous injection, has been approved as a botanical drug by TFDA. Hemorrhagic stroke will
induce secondary peri-blood clot edema and that may increase intracranial pressure to
exacerbate clinical symptom. Therefore, the purpose of the present study was to investigate
the efficacy of PG2 on hemorrhagic stroke.